| Dec 1, 2021 | Freenome | $300.0M Series D | Ellen Hukkelhoven, Peter Kolchinsky | Anzu Partners, Ameena El-Bibany, Vasudev Bailey, Artis Ventures (AV), Asset Management Ventures, Bain Capital Life Sciences, Cofounders Capital, Merck Global Health Innovation Fund, Polaris Partners, RA Capital, Section 32, Anne Wojcicki, Timothy A. Springer, Andreessen Horowitz, ArrowMark Partners, BrightEdge Ventures, Byers Capital, Catalio Capital Management, Data Collective, Eventide Asset Management, Farallon Capital Management, Fidelity Management & Research Company, Google Ventures, HBM Healthcare Investments, Intermountain Ventures, Janus Henderson Investors, Kaiser Permanente, Logos Capital, Novartis, Polaris Partners, Pura Vida Investments, Thomas Schinecker, Rock Springs Capital, Sands Capital, Soleus Capital, Suvretta Capital Management, T. Rowe Price Associates |
| Nov 9, 2021 | Arbor Biotechnologies | $215.0M Series B | Frank Yu, Chen Yu, Temasek | ARCH Venture Partners, ArrowMark Partners, Deep Track Capital, GreatPoint Ventures, Illumina Ventures, Janus Henderson Investors, Logos Capital, Ono Venture Investment, Piper Heartland Healthcare Capital, Section 32, Surveyor Capital, Tao Capital Partners, Tekla Capital Management, T. Rowe Price Associates, Vertex, Woodline Partners |
| Nov 1, 2021 | Quell Therapeutics | $160.0M Series B | Fidelity Management & Research Company, Rachel Mears, Wayne Holman, Houman Ashrafian | Lightstone Ventures, Soffinova Partners, SV Health Investors, Judith Hartley MBE, Janus Henderson Investors, Monashee Investment Management, Point72, Martin Murphy, Tekla Capital Management |
| Jul 1, 2021 | Turnstone Biologics | $80.0M Series D | Santhosh Palani, PhD, CFA, Point72 | KohFounders, Sofinnova Investments, venBio, Venrock, Versant Ventures, 404 Bio, Brace Pharma Capital, CaaS Capital Management, Eventide Asset Management, F-Prime Capital, JM Family Enterprises, Northleaf Capital Partners, OrbiMed, Sectoral Asset Management, Sixty Degree Capital, Surveyor Capital, Takeda Ventures, Teralys Capital |
| May 1, 2021 | TwinStrand Biosciences | $50.0M Series B | Section 32 | BoxGroup, GSR Ventures, Lightspeed China Partners, Madrona Ventures, Mayfield, Mischief Venture Capital, Third Rock Ventures, Jon Gelsey, Scott Belsky, Alexandria Venture Investments, Janus Henderson Investors, Soleus Capital |
| Mar 16, 2021 | Acepodia | $47.0M Series B | — | 8VC, CDIB Capital Group, DEFTA Partners, Wayne Holman |
| Mar 1, 2021 | Caribou Biosciences | $120.0M Series C | Farallon Capital Management, Santhosh Palani, PhD, CFA, Jeffrey Long-McGie | 1435 Capital Management, 6th Man Ventures, Afore Capital, DFJ, E1 Ventures, Flucas Ventures, Founders Co-op, Heavybit, Invariantes Fund, Kleiner Perkins, KRM Interests LLC, LombardStreet Ventures, Maverick Capital, Menlo Ventures, Mouro Capital, Necessary Ventures, QED Investors, Robert Bosch Venture Capital, Starbridge Venture Capital, Sterling Equity, William Guo, XStarPartners, Adam Marchick, Andy Rubin, Dylan Taylor, hugo angelmar, Ravi Grover, Richard Cooperstein, Rob Meyerson, Sri Batchu, Sung ho Choi, AbbVie Ventures, Adage Capital Management, Avego Bioscience Capital, Avidity Partners, Heritage Medical Systems, Invus, Janus Henderson Investors, LifeSci Venture Partners, Maverick Ventures, Monashee Investment Management, Point72, Pontifax, Tekla Capital Management, The Leukemia & Lymphoma Society |
| Mar 1, 2021 | Pyxis Oncology | $150.0M Series B | Christian Schetter, gotham makker | Pfizer Venture Investments, Acuta Capital Partners, Agent Capital, BVF Partners, Cormorant Asset Management, HBM Healthcare Investments, Janus Henderson Investors, Laurion Capital Management, Leaps by Bayer, LifeSci Venture Partners, Logos Capital, Longwood Fund, Perceptive Advisors, RA Capital Management, Surveyor Capital, Tekla Capital Management |
| Feb 4, 2021 | Reverie Labs | $25.0M Series A | Wayne Holman | — |
| Jan 5, 2021 | Aro Biotherapeutics | $88.0M Series A | Kevin Raidy, Shaan Gandhi | BioMotiv, BVF Partners, HealthCap, Ionis Pharmaceuticals, Johnson & Johnson Innovation |
| Jan 7, 2020 | TwinStrand Biosciences | $16.0M Series A | Terry Myerson | Alexandria Venture Investments, Sahsen Ventures |
| Nov 1, 2018 | Harpoon Therapeutics | $70.0M Series C | Arix Bioscience | Canaan Partners, Cormorant Asset Management, Lilly Asia Ventures, MPM Capital, New Leaf Venture Partners, NS Investment, Oncology Impact Fund, OrbiMed, Taiho Ventures |
| Sep 5, 2018 | 4D Molecular Therapeutics | $90.0M Series B | Viking Global Investors | Tony Yao, Berkeley Catalyst Fund, BVF Partners, Chiesi Ventures, CureDuchenne Ventures, Janus Henderson Investors, Mirae Asset, Perceptive Advisors |
| Sep 1, 2015 | Selecta Biosciences | $38.0M Series E | OrbiMed | 5AM Ventures, Advent Life Sciences, ARCH Venture Partners, Atlas Venture, Flagship Ventures, NanoDimension, Polaris Partners, The Column Group, AJU IB Investment, Flagship Ventures, Leukon Investments, NanoDimension, Osage University Partners, Polaris Partners, Rusnano, Sanofi Ventures, Sphera Healthcare |
| Aug 27, 2014 | Bellicum Pharmaceuticals | $55.0M Series C | — | AJU IB Investment, AVG Ventures, Jennison Associates, Joseph Edelman, RA Capital Management, Redmile Group, Remeditex Ventures, Sabby Capital |
